Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Two new projects led by Tal Arnon and Irina Udalova have been awarded Medical Research Council (MRC) funding.

Tal Arnon and Irina Udalova

Tal Arnon will study the role of resident memory B (BRM) cells in protecting the lungs infected with the influenza virus.

The MRC grant will enable the Arnon Lab to further understand how pre-existing antibodies provide immunity against influenza, which is a major threat to human health that causes over 500,000 deaths per year globally.  Tal’s lab has already led a pioneering study exploring the dynamic behaviour of a unique subset of memory B cells that develop within the lungs following infection with the influenza virus. The research can now continue to discover how these cells differentiate into antibody producing cells and their role in establising short- and long-term immunity against influenza virus.

Speaking about the funding Tal said: “We are very excited to receive this funding and to further explore the role of resident memory B cells in protecting against the flu virus. Understanding the molecular mechanisms that regulate this process will help to guide the development of new and more effective vaccine strategies to prevent the spread of influenza variants.” 

Irina Udalova’s MRC grant will enable the study of the mechanisms contributing to inflammatory bowel diseases (IBD) such as such as Crohn's disease (CD) and Ulcerative Colitis, which are estimated to affect 1 in every 100 people in the UK. Irina’s recent work decoded molecular wiring of innate immune cells, called neutrophils, and identified key control hubs amendable to tailored therapeutic targeting. “However, the specific role of neutrophils during colitis remains largely unexplored,” said Irina. The team will now be asking what role neutrophils play in the initiation of intestinal inflammation that leads to IBD.

Using cutting-edge imaging technology, single cell genomic approaches and unique tools modulating neutrophil activity in vitro and in vivo models, the team will examine the functional impact of controlled modulation of neutrophil activity on the intestinal inflammation. Irina hopes the project will lead to the development of a new class of therapeutic strategies, based on selective modulation of neutrophil biology. “This MRC award will allow us to build our knowledge of their role in disease and offers hope for future treatments of the condition,” said Irina.

 

Similar stories

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

NIHR funding for musculoskeletal and inflammatory disease research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients.

Leducq Foundation grant boosts cardiovascular research

The Leducq Foundation has awarded $7.5 million to researchers at the University of Oxford and their collaborators to advance immunotherapy as a treatment for cardiovascular disease, the leading cause of death in the UK.

Kennedy researchers awarded funding to improve the understanding of inflammatory bowel diseases

A new £1.5M grant from the Medical Research Council (MRC) to the Powrie Group at the Kennedy Institute will help define different pathotypes of inflammatory bowel diseases that could lead to better and more focused treatments for patients.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.